Other substances

Tipiracil 

A thymidine phosphorylase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Tipiracil is an uracil analogue that inhibits thymidine phosphorylase and has antineoplastic properties. It is used for the treatment of colorectal cancer (ChEBI). It was shown to inhibit the SARS-CoV-2 nsp15 endoribonuclease (Kim et al., 2021).

Tipiracil on DrugBank
Tipiracil on PubChem
Tipiracil on Wikipedia

Marketed as

TIPIRACIL HYDROCHLORIDE

 

Structure image - Tipiracil 

C1CC(=N)N(C1)CC2=C(C(=O)NC(=O)N2)Cl

Supporting references

Link Tested on Impact factor Notes Publication date
Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2
nsp15 Crystallization Enzyme assay In vitro 		in vitro enzye assay; crystallization; hACE-A549 cells; SARS-CoV-2 strain nCoV/Washington/1/2020 2.15

The compound displays inhibitory activity on SARS-CoV-2 Nsp15 endonuclease, likely as a uridine competitor. It also modestly inhibits the virus in a whole cell assay. The inhibitory effect is likely insufficient for clinical use, however, and the compound needs to be modified.

 Feb/09/2021
Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study
3CLpro Small molecule In silico 		in silico 2.09

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Sep/17/2020
Export (.csv)